GlassScriptPhysician profile
Amish Shah
NPI 1225057532
$3,984.41
in general payments reported to CMS, 2019-2025
27 companies · $568 in 2025
The $568 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $892 · 2020: $216 · 2021: $467 · 2022: $323 · 2023: $959 · 2024: $560 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,087.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $457.28 | 2019-2025 | |
| Amgen INC. | $448.19 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $424.10 | 2021-2025 | Verquvo, Belsomra |
| E.R. Squibb & Sons, L.L.C. | $405.02 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $312.52 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.92 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $286.57 | 2019-2024 | |
| Medtronic, INC. | $232.02 | 2021-2023 | Onyx Frontier |
| Cardiovascular Systems INC. | $147.77 | 2021 | |
| Janssen Pharmaceuticals, INC | $139.10 | 2019-2024 | Xarelto |
| Abbott Laboratories | $127.77 | 2023 | Aveir |
| Abbvie INC. | $121.43 | 2023 | Ubrelvy, Qulipta |
| Cvrx, INC. | $76.04 | 2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $66.48 | 2019-2024 | |
| Olympus America INC. | $64.96 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $42.19 | 2023 | Inpefa |
| Geron Corporation | $40.97 | 2025 | Rytelo |
| Boston Scientific Corporation | $40.76 | 2019-2025 | Cds - Mct/Cem Monitoring |
| Regeneron Healthcare Solutions, INC. | $38.83 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $36.32 | 2019-2020 | |
| Amarin Pharma, INC. | $35.34 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.70 | 2023-2025 | |
| Atricure, INC. | $24.87 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.26 | 2021 | |
| Allergan, INC. | $19.59 | 2019 | |
| Irhythm Technologies, INC. | $14.08 | 2020 | |
| Gilead Sciences, INC. | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amish Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.